The most effective on the market

Platelet Rich Plasma is used in a broad range of healing applications

What is GLO PRP?

Human blood contains among other things red blood cells, white blood cells and serum, or plasma, but also some amount of platelets (thrombocytes). Platelets are tiny cell fragments that circulate through our bloodstream. Platelets main responsibility is to stop the bleeding in case of injury.  Crucial function is also to repair wide range of injuries and diseases in both soft and hard tissues. This is possible due to many growth factors incorporated in platelets as part of the natural blood flow. If blood platelet count falls below normal, the condition is called thrombocytopenia. Platelet-rich plasma (PRP) is blood plasma that is enriched with platelets.  As a concentrated autologous (naturally derived from the same individual) platelets, PRP contains several different growth factors and other cytokines that stimulate healing of bone and soft tissues.

Preparation of the GLO PRP is simple and straight forward.  1 ml of Anticoagulant Citrate Dextrose Solution (ACD-A) or Sodium Citrate is added into a sterile GLO PRP syringe and 9 ml of whole blood is drawn from the patient. The GLO PRP syringe is then placed into a tube holder of the Glofinn's centrifuge and a counterweight is placed on a tube holder on the opposite side. The parameters of centrifugation is found in the Glofinn's centrifuge manual. A patented GLO PRP Kit separates plasma and red blood cells (RBC) by separating the RBC into the attached RBC collector.  After removing the RBC collector, PRP concentrates are found at the bottom of the tube.  PRP concentrates are ready to draw directly into an injection syringe for a procedure / applications.  The concentration of PRP is adjustable by varying the amount of utilizable dose.

Use of PRP procedure has 40+ years of history, showing its benefits in various healthcare and medical industry.  PRP has been successfully applied in many fields, such as orthopedics, sports medicine, wound healing, aesthetic surgery, dentistry, otolaryngology, neurosurgery, ophthalmology, urology, veterinary, prolotherapy, cardiothoracic and maxillofacial surgery.

Disclaimer


For US visitors,

Glofinn.com is an international website that has not been evaluated by the United States Food and Drug Administration (FDA) and statements / claims shown on the website is not intended to diagnose, treat, cure or prevent disease. Information provided on the website or any information contained on or in any product/packaging labels is for information purpose only and is not intended as a substitute for advice from your physician or other health care professional.

Information shown on the site may describe clearances in countries other than the United States, and therefore may contain indications and information that are outside the scope of the FDA-cleared labeling. Please review the material accordingly.

Contact Us


Glofinn Oy is a biotechnology & medical research firm in charge of sales, marketing and distribution in Europe. Glotech Ltd. is a Korean based medical research firm and the manufacturer of GLO PRP products. Glofinn America, LLC manages sales, marketing, and distribution in the Americas, Asia, Middle East and Oceania

Please contact us for more product detail.

Extranet

Recent posts

  • 28.07.2016
    The Effectiveness of Platelet-Rich Plasma in the Treatment of Tendinopathy

    The Effectiveness of Platelet-Rich Plasma in the Treatment of Tendinopathy

    A Meta-analysis of Randomized Controlled Clinical Trials

    1.Jane Fitzpatrick, MBBS, FACSP*,2.,Max Bulsara, BSc(Hons), MSc, PhD and 3. Ming H. Zheng, MD, PhD, FRCPath, FRCPA

    1.University of Western Australia, Perth, Australia,  2.‡University of Notre Dame Australia, Freemantle, Australia, 3.*Jane Fitzpatrick, MBBS, FACSP, University of Western Australia, 35 Stirling Highway, M508 Crawley, WA, 6009 Australia (email: jane.fitzpatrick@research.uwa.edu.au).

    Abstract

    Background: Tendinopathy is very common in the general population. There are increasing numbers of clinical studies referring to platelet-rich plasma (PRP) and platelet-poor plasma (PPP) as treatments for tendinopathy.

    Purpose: To perform a meta-analysis of the outcomes of the PRP groups by preparation method and injection technique in tendinopathy. To determine the clinical effectiveness of the preparations and to evaluate the effect of controls used in the studies reviewed.

    Study Design: Systematic review and meta-analysis.

    Methods: The PubMed, EMBASE, CINAHL, and Medline databases were searched in March 2012, April 2014, and August 2015, and randomized controlled trials using autologous blood, PRP, PPP, or autologous conditioned plasma in tendinopathy with outcome measures of pain and follow-up time of 3 months were included in this review. Trials including surgery, tendon tears, and muscle or ligament injuries were excluded. Study quality was assessed using the Cochrane Collaboration risk-of-bias tool by 2 reviewers. Data were pooled using random-effects meta-analysis. The primary outcome measure was a change in pain intensity. Where more than 1 pain scale was included, a functional score was selected ahead of a visual analog scale score.

    Results: A total of 18 studies (1066 participants) were included. Eight studies were deemed to be at low risk of bias. The most significant outcomes in the PRP groups were seen in those treated with highly cellular leukocyte-rich PRP (LR-PRP) preparations: GPS kit (standardized mean difference [SMD], 35.75; 95% CI, 28.40-43.10), MyCells kit (SMD, 31.84; 95% CI, 17.56-46.13), Prosys kit (SMD, 42.99; 95% CI, 37.73-48.25), and unspecified LR-PRP (SMD, 34.62; 95% CI, 31.69-37.55). When the LR-PRP system types were grouped, there was a strongly positive effect (SMD, 36.38; 95% CI, 34.00-38.77) when compared with leukocyte-poor PRP (SMD, 26.77; 95% CI, 18.31-35.22). In assessing the control groups, there was no clear difference between different types of control injections: saline (SMD, 14.62; 95% CI, 10.74-18.50), local anesthetic (SMD, 15.00; 95% CI, 7.66-22.34), corticosteroid (SMD, 23.82; 95% CI, 10.74-18.50), or dry needling (SMD, 25.22; 95% CI, 21.27-29.16).

    Conclusion: There is good evidence to support the use of a single injection of LR-PRP under ultrasound guidance in tendinopathy. Both the preparation and intratendinous injection technique of PRP appear to be of great clinical significance.

    Keywords: platelet-rich plasma, tendinitis, tendinopathy, platelet separation system, meta-analysis, injection therapy

    Footnotes

    The authors declared that they have no conflicts of interest in the authorship and publication of this contribution.

    Read More
  • 28.07.2016
    Platelet-Rich Plasma Obtained with Different Anticoagulants and Their Effect on Platelet Numbers and Mesenchymal Stromal Cells Behavior In Vitro

    Platelet-Rich Plasma Obtained with Different Anticoagulants and Their Effect on Platelet Numbers and Mesenchymal Stromal Cells Behavior In Vitro

    Ronaldo José Farias Corrêa do Amaral,1,2 Nemias Pereira da Silva,1 Natália Ferreira Haddad,1 Luana Siqueira Lopes,1 Fábio Dias Ferreira,1 Ricardo Bastos Filho,3 Paola Alejandra Cappelletti,1 Wallace de Mello,1,4 Eric Cordeiro-Spinetti,2 and Alex Balduino1,2

    1Excellion Serviços Biomédicos, Amil/UnitedHealth Group, 25651-000 Petrópolis, RJ, Brazil
    2Laboratório de Biologia e Tecnologia Celular, Universidade Veiga de Almeida, 20270-150 Rio de Janeiro, RJ, Brazil
    3Universidade Federal Fluminense, 24033-900 Niterói, RJ, Brazil
    4Centro Universitário Celso Lisboa, 20950-091 Rio de Janeiro, RJ, Brazil

    Received 8 January 2016; Revised 9 April 2016; Accepted 27 April 2016

    Academic Editor: Jiabing Fan

    Copyright © 2016 Ronaldo José Farias Corrêa do Amaral et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


    Abstract

    There are promising results in the use of platelet-rich plasma (PRP) for musculoskeletal tissue repair. However, the variability in the methodology for its obtaining may cause different and opposing findings in the literature. Particularly, the choice of the anticoagulant is the first definition to be made. In this work, blood was collected with sodium citrate (SC), ethylenediaminetetraacetic acid (EDTA), or anticoagulant citrate dextrose (ACD) solution A, as anticoagulants, prior to PRP obtaining. Hematological analysis and growth factors release quantification were performed, and the effects on mesenchymal stromal cell (MSC) culture, such as cytotoxicity and cell proliferation (evaluated by MTT method) and gene expression, were evaluated. The use of EDTA resulted in higher platelet yield in whole blood; however, it induced an increase in the mean platelet volume (MPV) following the blood centrifugation steps for PRP obtaining. The use of SC and ACD resulted in higher induction of MSC proliferation. On the other hand, PRP obtained in SC presented the higher platelet recovery after the blood first centrifugation step and a minimal change in MSC gene expression. Therefore, we suggest the use of SC as the anticoagulant for PRP obtaining.

    Read More
  • 29.04.2016
    GLOFINN Distributor Meeting on 12th-13th of May 2016 Barcelona, Spain

    We are happy to announce that the GloFinn Distributor Meeting is going to take place in Barcelona, Spain thu-fri 12th-13th of May.

    The Venue for the Meeting is Best Western Hotel Mediterraneo.

    Read More